-
Product Insights
Pancreatic Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Pancreatic Diseases - Drugs In Development, 2023’, provides an overview of the Pancreatic Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatic Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Endocrine Gland Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Endocrine Gland Disorders - Drugs In Development, 2023’, provides an overview of the Endocrine Gland Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endocrine Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LYGLIV-0001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LYGLIV-0001 Drug Details LYGLIV-0001 is under development for the treatment of end-stage liver disease...